Clinical trials: Advanced and/or Metastatic Solid Tumours
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or…
- Trial name
- NCT04052204
- Testing
- avelumab, Bempegaldesleukin, talazoparib
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Colorectal Cancer, Gastric Cancer
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
This is a Phase 1 open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced micro satellite-stable (MSS)…
- Conditions
- Colorectal Cancer, Gastric Cancer, Ovarian Cancer
- Trial name
- NCT05427487
- Testing
- IVX037, Sintilimab
- Where
- 3 sites in Australia
- Volunteers
- 70 people
- Sponsor
- ImmVirx Pty Ltd
Solid Tumors, Metastatic Cancer
Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors
The aim of this research is to evaluate the potential interest of an association of Pazopanib, a multi-tyrosine kinase inhibitor, and cisplatin.
- Trial name
- PACIFIK (NCT01165385)
- Testing
- cisplatin, Pazopanib
- Where
- 5 sites in France
- Volunteers
- 35 people
- Sponsor
- UNICANCER
Neoplasms, Metastatic Cancer
Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.
The main purpose of this study is to determine if AZD8931 can be safely administered in Japanese patients alone and in combination with weekly paclitaxel.
- Conditions
- Neoplasms, Metastatic Cancer, Breast Cancer
- Trial name
- NCT01003158
- Testing
- AZD8931, Paclitaxel
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Solid Tumor, Metastatic Cancer
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
The purpose of this first-in-human (FIH) study is to determine the maximum tolerated dose (MTD) and to characterize the safety, tolerability, PK, and dosimetry profile of [177Lu]Lu-SN201 in adult participants with advanced solid…
- Conditions
- Solid Tumor, Metastatic Cancer, Unresectable Solid Tumor, Recurrent Solid Tumor
- Trial name
- Tumorad (NCT06184035)
- Testing
- [177Lu]Lu-SN201
- Where
- 2 sites in Australia
- Volunteers
- 90 people
- Sponsor
- Spago Nanomedical AB
Solid Tumor, C-Met Mutation-Related Tumors
Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161
Safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy evaluation of the selective c-MET inhibitor GST-HG161 in patients with advanced or metastatic solid tumors: An open, single and multiple…
- Trial name
- NCT04228406
- Testing
- GST-HG161
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
- Trial name
- NCT05678998
- Testing
- WTX-330
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Werewolf Therapeutics, Inc.
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
This phase II trial studies the effect of larotrectinib in treating patients with NTRK gene amplification positive solid tumors that have spread to nearby tissues or lymph nodes (locally advanced) or other places in the body…
- Trial name
- NCT04879121
- Testing
- Larotrectinib Sulfate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors Harboring a TP53 Y220C Mutation
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GenSci128 Tablet in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation
- Trial name
- NCT06908434
- Testing
- GenSci128 tablets
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Advanced Solid Tumors
Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors
This study is an open-label, dose-escalation phase I clinical trial conducted in patients with advanced or metastatic solid tumors in China.This study is an open-label, dose-escalation phase I clinical trial conducted in patients…
- Trial name
- NCT07438093
- Testing
- Peginterferon α-2b plus an anti-PD-1
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Solid Tumors
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics and activity of Selicrelumab administered in combination with Atezolizumab (ATZ) in participants with metastatic or…
- Trial name
- NCT02304393
- Testing
- Atezolizumab, Selicrelumab
- Where
- 11 sites in United States, Canada and 4 more
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Lymphoma
Intratumoral CAN2109 in Subjects With Solid Tumors
A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.
- Trial name
- NCT06332430
- Testing
- CAN2109
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Canwell Biotech Limited
Unspecified Adult Solid Tumor, Protocol Specific
Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of entolimod in treating patients with locally advanced or metastatic solid tumors that cannot be removed by surgery.
- Trial name
- NCT01527136
- Testing
- entolimod, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic or Locally Advanced Unresectable Solid Tumors
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
This is an open-label, multicenter, clinical study conducted in multiple parts to establish the safety, tolerability, Pharmacokinetic/Pharmacodynamic (PK/PD) profile, maximum tolerated dose (MTD) combinations (if observed) and…
- Trial name
- NCT05396833
- Testing
- Tuvusertib, Lartesertib, Avelumab
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Solid Tumor, Lymphoma
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
The potency of immune checkpoint blockade is limited in most solid malignancies, one possible reason for which is tumor microenvironment.
- Trial name
- NCT04407741
- Testing
- SHR2554+SHR1701, SHR1701
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Urothelial Carcinoma (UC), Solid Tumors
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
This study is a single-arm, open-label, multicenter, non-randomized phase IIa/IIb clinical study to evaluate the efficacy and safety of BL-M09D1 for injection in patients with locally advanced or metastatic urothelial carcinoma…
- Trial name
- NCT07837622
- Testing
- BL-M09D1
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Melanoma (Skin), Cutaneous Melanoma
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or…
- Conditions
- Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor
- Trial name
- NCT05578872
- Testing
- ANV419
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 29 people
- Sponsor
- Anaveon AG
Malignant Solid Tumor, Metastatic EphA2 Positive Cancer
Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
This was a Phase 1, dose-escalation, non-randomized, open-label, single-center study of DS-8895a in patients with advanced or metastatic Ephrin type-A receptor 2 (EphA2)-positive cancers.
- Trial name
- LUD2014-002 (NCT02252211)
- Testing
- DS-8895a 1 mg/kg, DS-8895a 3 mg/kg, DS-8895a 10 mg/kg
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Locally Advanced or Metastatic Solid Tumors
Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid Tumors
This research design for center, increasing openness, dose and dose extension phase I clinical trials, research the main evaluation BAT6005 injection single drug in patients with advanced malignant solid tumors in the safety…
- Trial name
- NCT05116709
- Testing
- BAT6005 injection
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Bio-Thera Solutions
Solid Tumor
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
To evaluate safety, tolerance and efficacy of TASO(TGF-β2 targeting anti-sense oligonucleotide)-001 in combination with recombinant interleukin-2(Aldesleukin) in advanced or metastatic solid tumor and to find appropriate dose for…
- Trial name
- NCT04862767
- Testing
- TASO-001((TGF-β2 targeting anti-sense oligonucleotide), Aldesleukin
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Autotelicbio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.